垂体泌乳素腺瘤诊治共识(2025版)
中国垂体腺瘤协作组基于2014版共识,结合最新循证医学证据与临床经验修订本共识,系统阐述垂体泌乳素腺瘤的流行病学、临床表现、诊断标准、鉴别诊断流程及治疗策略,并针对妊娠期妇女、男性患者和难治性病例提出个体化管理建议,共形成36条推荐意见。
要点
- 治疗决策强调多学科团队综合研判,包含神经外科、内分泌科、放射影像科、放射治疗科、病理科、眼科、妇产科等。
- 共识针对筛查、评估、诊断、治疗、监测等方面形成36条推荐意见。
- 共识对妊娠期妇女、男性患者和难治性病例提出个体化管理建议。
核心结论
- 共识兼顾临床需求与国际循证标准,为垂体泌乳素腺瘤诊疗提供高信度参考,有望提升我国诊治规范化及整体水平。
研究设计与样本
- 中国垂体腺瘤协作组基于2014版《中国垂体催乳素腺瘤诊治共识》,根据最新循证医学证据和临床实践经验修订本共识;通过推荐问题提出、证据总结和评价、推荐意见形成、专家讨论,结合临床实践形成36条推荐意见。
诊断标准与关键数值
- 共识系统阐述垂体泌乳素腺瘤的诊断标准与鉴别诊断流程,并针对筛查、评估、诊断、治疗、监测形成36条推荐意见。
临床应用与阅片要点
- 治疗决策强调应由多学科专家团队进行综合研判,包含神经外科、内分泌科、放射影像科、放射治疗科、病理科、眼科、妇产科等。
- 共识针对妊娠期妇女、男性患者和难治性病例提出个体化管理建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pituitary prolactinoma, the most prevalent functional pituitary adenomas, has witnessed significant advancements in diagnostic and therapeutic concepts with the advancement of surgical techniques and the update of more clinical evidence-based medical evidence. Based on the 2014 version of the "Chinese Consensus on the Diagnosis and Treatment of Pituitary Prolactin Adenoma", the China Pituitary Adenoma Specialist Council has revised this consensus, in accordance with the latest evidence-based medical evidence and clinical experience, aiming to provide standardized diagnosis and treatment suggestions for clinicians. The consensus systematically expounds the epidemiological characteristics, clinical manifestations, diagnostic criteria, differential diagnosis process and treatment strategies of prolactinomas, and puts forward individualized management suggestions for special populations (such as pregnant women, male patients and refractory prolactinomas). The treatment decision strongly advocates for multidisciplinary team evaluation involving specialists from neurosurgery, endocrinology, radiology, radiation oncology, pathology, ophthalmology, and obstetrics/gynecology, etc. Through the raising of recommendation questions, summary and evaluation of evidence, formation of recommendation opinions, expert discussions, and in combination with clinical practice, 36 recommendations have been formed in aspects such as screening, assessment, diagnosis, treatment, and monitoring. This consensus takes into account both clinical needs and international evidence-based standards, providing a highly reliable reference for diagnosis and treatment, and is expected to enhance the standardization and overall level of prolactinoma diagnosis and treatment in China.
垂体泌乳素腺瘤是最常见的功能性垂体肿瘤,随着外科技术进步和更多临床循证医学证据的更新,垂体泌乳素腺瘤的诊治理念发生了较大变化。中国垂体腺瘤协作组基于2014版《中国垂体催乳素腺瘤诊治共识》,根据最新循证医学证据和临床实践经验,重新制订本共识,旨在为临床医师提供规范化诊疗建议。共识系统性地阐述了垂体泌乳素腺瘤的流行病学特征、临床表现、诊断标准、鉴别诊断流程以及治疗策略,并针对特殊人群(如妊娠期妇女、男性患者和难治性病例)提出了个体化管理建议。治疗决策强调应由多学科专家团队进行综合研判,包含神经外科、内分泌科、放射影像科、放射治疗科、病理科、眼科、妇产科等。通过推荐问题提出、证据总结和评价、推荐意见形成、专家讨论,结合临床实践,针对筛查、评估、诊断、治疗、监测等方面形成了36条推荐意见。本共识兼顾临床需求与国际循证标准,为诊疗提供高信度参考,有望提升我国垂体泌乳素腺瘤诊治的规范化以及整体水平。.
引用
- [Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)]. Zhonghua Yi Xue Za Zhi. 2025. PMID: 41218892. doi:10.3760/cma.j.cn112137-20250806-01985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。